G9a与DNMT双靶向在多发性骨髓瘤中诱导抗肿瘤效应
多发性骨髓瘤(MM)中G9a与DNA甲基转移酶(DNMTs)活性升高且与不良预后相关。研究采用小分子抑制剂联合处理,发现G9a与DNMTs协同沉默关键抑癌基因;双抑制降低原代MM细胞活力并诱导MM细胞系凋亡,伴随凋亡相关基因表达升高及IRF4、XBP1、MYC蛋白水平下降。在体内异种移植MM模型中,G9a抑制剂A366与DNMTs抑制剂地西他滨协同促进显著肿瘤消退。
要点
- G9a与DNMTs在MM中活性升高,与不良预后相关。
- 双抑制降低原代MM细胞活力并诱导MM细胞系凋亡。
- A366与地西他滨在体内异种移植MM模型中协同促进肿瘤消退。
核心结论
- G9a与DNMTs协同调控MM中的基因沉默,双表观遗传抑制是有前景的治疗策略。
研究设计与样本
- 体外研究采用小分子抑制剂联合处理MM细胞,并进行组蛋白H3赖氨酸二甲基化分布、DNA甲基化组和转录组分析。
- 体内研究在临床前异种移植MM模型中评估联合治疗。
主要发现
- G9a与DNMTs协同沉默关键抑癌基因。
- 双抑制降低原代MM细胞活力并诱导MM细胞系凋亡。
- 凋亡相关基因表达升高,IRF4、XBP1和MYC蛋白水平降低。
- G9a抑制剂A366与DNMTs抑制剂地西他滨协同促进体内显著肿瘤消退。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Multiple myeloma (MM) is a hematological disease of the plasma cell that remains clinically challenging despite the development of novel therapies. Epigenetic alterations have been demonstrated to contribute to MM pathogenesis, yet comprehensive studies into the links between different epigenetic regulatory systems in myeloma progression and drug resistance, though clinically relevant, are largely lacking. G9a and the DNA methyltransferases (DNMTs) are epigenetic modifiers that exhibit increased activity in MM, correlating with poor prognosis. To investigate the partnership between G9a and DNMTs, we used a combinatorial treatment approach involving small-molecule inhibitors. In-depth molecular analysis of the histone H3 lysine dimethylation distribution, the DNA methylome and the transcriptome of MM revealed a silencing mechanism involving G9a and DNMTs that represses key tumor suppressor genes. Moreover, dual inhibition of G9a and DNMTs reduced cell viability in primary MM cells and induced apoptosis in MM cell lines. This was accompanied by increased expression of apoptosis-related genes and decreased protein levels of the MM-associated oncoproteins IRF4, XBP1, and MYC. To assess the translational relevance of our in vitro findings, we evaluated the combination therapy in an in vivo preclinical xenograft MM model. Specifically, we demonstrate that the G9a inhibitor A366 synergizes with the DNMTs inhibitor decitabine to promote a robust tumor regression in vivo. Together, these data provide new insights into the cooperative role of G9a and the DNMTs in regulating gene silencing in MM, and support dual epigenetic inhibition as a promising therapeutic strategy.
引用
- Nylund P, Garrido-Zabala B, Tziola SI, et al. Dual targeting of G9a and DNMTs induces antitumor effects in multiple myeloma. Blood Adv. 2025. PMID: 40674720. doi:10.1182/bloodadvances.2023010571
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。